Abstract
Modulation of gamma-secretase cleavage of Amyloid Precursor Protein (APP) to control the level of Amyloidbeta (A-beta) peptide is one of the strategies to develop therapy for Alzheimer’s disease. Presenilin is a subunit and the catalytic core of gamma-secretase. It has Asp 257 and Asp 385 residues, which are essential for catalytic activity and thus serve as the region of interest for screening of potential gamma-secretase inhibitors. In the present study, in silico screening of drug molecules has been performed in an attempt to identify effective inhibitors of presenilin. Ligand-based pharmacophore models generated with reported inhibitor molecules have been used as query for screening from DrugBank database. Inhibitory activity (IC50) of the screening hits is predicted using a QSAR model developed. The selected molecules have been subjected to docking study against Presenilin1 C-terminal fragment that houses Asp 385 in place of presenilin, as its structure is unavailable. Finally, 46 potential inhibitor molecules were selected based on scores of scoring function and interaction with Asp 385. The selected compounds have spatial arrangement of features essential for binding to presenilin, desired inhibitory activity against processing of APP to A-beta by gamma-secretase and selective interaction with specific amino acids in ligand-protein docked complexes.
Keywords: Alzheimer’s disease, drugs, gamma-secretase, IC50, inhibitors, ligand-based pharmacophore model, QSAR, screening.
Combinatorial Chemistry & High Throughput Screening
Title:In Silico Screening of Drugs to Find Potential Gamma-Secretase Inhibitors Using Pharmacophore Modeling, QSAR and Molecular Docking Studies
Volume: 17 Issue: 9
Author(s): Arun Ekiri Vaidyanathan Raman, Karthic Krishnan, Arun Maurya and Nandini Sarkar
Affiliation:
Keywords: Alzheimer’s disease, drugs, gamma-secretase, IC50, inhibitors, ligand-based pharmacophore model, QSAR, screening.
Abstract: Modulation of gamma-secretase cleavage of Amyloid Precursor Protein (APP) to control the level of Amyloidbeta (A-beta) peptide is one of the strategies to develop therapy for Alzheimer’s disease. Presenilin is a subunit and the catalytic core of gamma-secretase. It has Asp 257 and Asp 385 residues, which are essential for catalytic activity and thus serve as the region of interest for screening of potential gamma-secretase inhibitors. In the present study, in silico screening of drug molecules has been performed in an attempt to identify effective inhibitors of presenilin. Ligand-based pharmacophore models generated with reported inhibitor molecules have been used as query for screening from DrugBank database. Inhibitory activity (IC50) of the screening hits is predicted using a QSAR model developed. The selected molecules have been subjected to docking study against Presenilin1 C-terminal fragment that houses Asp 385 in place of presenilin, as its structure is unavailable. Finally, 46 potential inhibitor molecules were selected based on scores of scoring function and interaction with Asp 385. The selected compounds have spatial arrangement of features essential for binding to presenilin, desired inhibitory activity against processing of APP to A-beta by gamma-secretase and selective interaction with specific amino acids in ligand-protein docked complexes.
Export Options
About this article
Cite this article as:
Raman Ekiri Vaidyanathan Arun, Krishnan Karthic, Maurya Arun and Sarkar Nandini, In Silico Screening of Drugs to Find Potential Gamma-Secretase Inhibitors Using Pharmacophore Modeling, QSAR and Molecular Docking Studies, Combinatorial Chemistry & High Throughput Screening 2014; 17 (9) . https://dx.doi.org/10.2174/1386207317666141019195448
DOI https://dx.doi.org/10.2174/1386207317666141019195448 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Induced QT Prolongation: Lessons from Congenital and Acquired Long QT Syndromes
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot topic: Inflammation, Immunity, and Alzheimers Disease (Guest Editor: Terrence Town)]
CNS & Neurological Disorders - Drug Targets The Perils of Alzheimers Drug Development
Current Alzheimer Research Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease
Current Alzheimer Research Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Aluminum Excytotoxicity and NeuroAutotoImmunity: The Role of the Brain Expression of CD32+ (FcγRIIa), ICAM-1+ and CD3ع in Aging
Current Aging Science Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Cell Death Targets and Potential Modulators in Alzheimers Disease
Current Pharmaceutical Design Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery
Current Neuropharmacology Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Carotid Artery Disease: Current Concepts on Endothelial Dysfunction and Matrix Remodeling
Current Drug Therapy A New Regulatory Road-Map for Alzheimer’s Disease Drug Development
Current Alzheimer Research Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Anti-α4β1 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Drosophila melanogaster in the Study of Human Neurodegeneration
CNS & Neurological Disorders - Drug Targets Fetzima (levomilnacipran), a Drug for Major Depressive Disorder as a Dual Inhibitor for Human Serotonin Transporters and Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1
CNS & Neurological Disorders - Drug Targets Persistent Psychosis from Toluene Exposure; More Likely Coincidence than Cause: A Review of our Experience and the Literature
Current Psychiatry Reviews A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry